epirubicin has been researched along with Hepatitis B Virus Infection in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chau, TN; Cheung, WI; Fung, KS; Lam, YK; Leung, VK; Lin, SY; Lo, FH | 1 |
| Chang, MC; Chao, TY; Chen, LT; Chen, PJ; Cheng, AL; Hsiung, CA; Hsu, CH; Kao, WY; Su, IJ; Tien, HF; Tsao, CJ; Uen, WC; Whang-Peng, J | 1 |
| Chuma, M; Harabayashi, T; Higashiyama, H; Hige, S; Nonomura, K; Shinohara, N | 1 |
1 trial(s) available for epirubicin and Hepatitis B Virus Infection
| Article | Year |
|---|---|
Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carrier State; Cyclophosphamide; Epirubicin; Etoposide; Female; Hepatitis B; Hepatitis B virus; Humans; Lymphoma; Male; Middle Aged; Prednisolone; Risk Factors; Survival Analysis; Treatment Outcome; Virus Activation | 2003 |
2 other study(ies) available for epirubicin and Hepatitis B Virus Infection
| Article | Year |
|---|---|
Prospective evaluation of seropositive occult hepatitis B viral infection in lymphoma patients receiving chemotherapy.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Carrier State; Cyclophosphamide; DNA, Viral; Epirubicin; Female; Guanine; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Liver Function Tests; Lymphoma; Male; Middle Aged; Prednisolone; Prospective Studies; Rituximab; Time Factors; Vincristine; Viral Load | 2011 |
Reactivation of hepatitis in a bladder cancer patient receiving chemotherapy.
Topics: Antineoplastic Agents; Cisplatin; Epirubicin; Female; Hepatitis B; Humans; Methotrexate; Middle Aged; Recurrence; Urinary Bladder Neoplasms | 2007 |